Akums Drugs & Pharmaceuticals Ltd Q4 FY25 Earnings Analysis

- CDMO business aims for volume growth of 4%-5% to achieve approx. 12%-13% revenue growth. - Historically, the company has achieved 6%-8% volume growth annually, 2-2.5x higher than the market. - Recent 12-month trailing volume growth in CDMO is 1.6%, while industry was flat. - Q4 and Q1 outlook for CDMO volume growth appears positive with visible order book. - New European CDMO contract expected to contribute revenues starting CY 2027, spread evenly over contract length till 2032. - API business is rationalizing portfolio, aiming for breakeven in 1 to 2 years. - Focus on higher-margin and regulated market products to improve API revenues. - Branded generics and trade generic margins expected to improve gradually, augmenting revenue growth. - Overall, growth is linked to sustaining market share, improving product mix, and expanding in regulated markets like Europe.

- CDMO business volume growth expected at 4-5% in near term, targeting overall revenue growth of 12-13%. - European contract (EUR 200 million over duration) to commence commercial supply in 2027, spreading revenues until 2032, providing significant growth. - API business is undergoing rationalization; breakeven expected in 1 to 2 years with focus on high-margin, diversified products and regulated market exports. - Branded generics and Unosource expected to deliver higher EBITDA margins (18-20%) versus overall CDMO segment (~15.4%). - R&D investments continue, INR 94 crores in 9 months FY25 aimed at driving new product approvals (17 DCGI approvals FY25 so far). - Overall, business should see similar revenues and EBITDA to current performance in the short term, with growth accelerated by new contracts and product mix improvements over next 1-3 years. - Company targets to sustain and grow earnings through volume growth, better product mix, and greater regulatory approvals.

- incurred capex of INR 191 crores in 9 months of FY '25, largely in the CDMO vertical - planned capex of INR 175-200 crores annually over next 2 years to commission new plants and production lines - INR 32 crores capex over next 2 quarters to upgrade and improve R&D capabilities, focusing on regulated markets and niche dosage forms - expanding and increasing manufacturing capabilities for nasal sprays, eye drops, bi-layered tablets, ampoules, FFS small volume parenterals - plans to expand into large volume parenterals, dry powder injectable, and lyophilized vials soon - expanding/upgrading Mumbai R&D facility, moving to owned property to enhance product development and customer engagement

- The transcript does not mention any plans for new fundraising through debt or equity in the near future. - The company’s cash flow and free cash flow have improved significantly, with free cash flow turning positive in Q3 FY25. - Current debt stands at INR 322 crores, down from pre-IPO levels. - The company continues to invest in capex, mainly through internal cash flows, with planned capex of INR 175-200 crores annually for the next two years. - No explicit mention was made about raising fresh debt or equity for funding these investments. - Overall, the focus appears on optimizing existing resources and cash flows rather than raising new capital through fundraising.

- The company has visibility on its order book for the next 60 days (Q4 FY25) and expects decent volume growth in this quarter. - New contracts discussed earlier are expected to commercialize starting calendar year 2027 (likely Q4 2027 or Q1 next fiscal). - The recently signed European contract worth EUR 200 million is expected to commence revenues in CY 2027 and will be spread evenly across years. - Management expressed confidence in securing more contracts in Europe over the next 2 to 3 years, following the successful commencement of the first contract. - Current order execution for the next six months is primarily reflected in Q4 FY25 with encouraging volume growth envisaged, though details for the entire next fiscal are not disclosed.